MEISi-2 |
| Catalog No.GC62299 |
MEISi-2는 조혈모세포(HSC) 자가 재생의 핵심 조절자인 MEIS의 선택적 억제제입니다. MEISi-2는 심장 손상, 조혈 문제, 골수 이식 및 암 연구를 위해 개발되었습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2250156-71-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer[1].
MEISi-2 does not significantly inhibit the PBX-Luc-reporter[1].MEISi-2 induces MEIS dependent hematopoietic stem cell maintenance and self-renewal[1].MEISi-2 down-regulates MEIS target gene expression[1].MEISi-2 induces murine (LSKCD34low cells) and human (CD34+, CD133+, and ALDHhi cells) HSC self-renewal ex vivo[1].
MEISi-2 (10 µM; i.p.; at day 1, day 4 and day 7) functionally inhibits MEIS in vivo, thus they induces c-Kit+ cell, Sca1+ cell, CD150+ cell, LSK HSPCs, LSKCD34low HSC content and LSKCD150+CD48- HSC content[1].MEISi-2 down-regulates Meis1 expression, Hif-2α, and key CDKI gene expression including p16, p19, p19ARF[1].
[1]. Raife Dilek Turan, et al. Development of Small Molecule MEIS Inhibitors that modulate HSC activity. Sci Rep. 2020; 10: 7994.
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *